Gilead Sciences
Search results
At Hetero, our every action seeks to inspire human belief in accessibility and affordability of life-saving medicines across the world. With unparalleled strengths in pharmaceutical research, manufacturing, and marketing, we are positioned to serve people regardless of geographies.
Hetero Labs Limited 301, 3rd Floor, B wing, Sunteck Centre, Subhash Road, Vile Parle (E), Mumbai - 400 057, India. Tel: +91-22-66910809 Mumbai (Domestic Marketing – APIs & FDFs)
Hetero Healthcare Ltd is a leading Innovative Pharmaceutical Company in India, headquartered at Hyderabad. We aim to improve the quality life of the people with our product line and along with a continuous Research and Development process.
As the leading developer of biosimilars within the Hetero Group, Hetero Biopharma is steadily establishing itself with unparalleled strengths in providing the best pharmaceutical research, manufacturing, and marketing capabilities across the globe.
Over the past two decades, the company evolved itself as one of the largest producers of APIs globally and a leader in ARV APIs and FDFs. Today, Hetero is among the leading and largest privately held pharmaceutical company in India.
The birth of Hetero Biopharma in 2009 marked a new era in the field of biopharmaceuticals. An R&D unit was established, and within a short time, the company became a manufacturer of affordable medicines accessible to people worldwide.
HETERO LABS LIMITED - India | 25,744 followers on LinkedIn. Please follow Hetero's official page, https://www.linkedin.com/company/hetero/ | HETERO LABS LIMITED - India is a...
HETERO LABS LIMITED BADDI formulation unit was founded in the year 2003. Dr.B.P.S.Reddy (Chairman) Under his leadership, HETERO has risen to become a world leader in the production of anti-retroviral drugs, partner of choice for customers and a globally trusted brand for high quality medicines.
Hetero Announces Interim Clinical Results from Phase III Clinical Trials of Molnupiravir conducted in India. Hetero’s Biosimilar Version of Tocilizumab (Tocira) receives Emergency Use Authorization (EUA) from DCGI for the treatment of Covid-19 in hospitalized adults.
Hetero Labs Limited is a Public incorporated on 10 March 1989. It is classified as Non-government company and is registered at Registrar of Companies, ROC Hyderabad. Its authorized share capital is Rs. 3,200,000,000 and its paid up capital is Rs. 2,770,560,000.
